Publication
Title
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation : a study from the myeloproliferative neoplasm subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
Author
Institution/Organisation
Chronic Malignancies Working Party
Abstract
Transformed acute myeloid leukemia in myelofibrosis results in a median survival of less than 5 months. We identified 46 of 1048 myelofibrosis patients in the European Group for Blood and Marrow Transplantation registry who received allogeneic stem cell transplantation for acute leukemia evolving from myelofibrosis. The cumulative incidence of treatment-related mortality at 1 year was 28% (95% confidence interval, 14 to 42) and of relapse at 3 years was 47% (95% confidence interval, 31 to 63). The 3-year progression-free (PFS) and overall survival (OS) rates were 26% and 33%, respectively. The only significant factor for survival was complete remission versus no complete remission before transplantation (69% versus 22%, P = .008); however, complete remission was achieved only in 8 patients. Allogeneic stem cell transplantation can cure myelofibrosis patients transformed to leukemia. (C) 2014 American Society for Blood and Marrow Transplantation.
Language
English
Source (journal)
Biology of blood and marrow transplantation. - -
Publication
2014
ISSN
1083-8791
Volume/pages
20:2(2014), p. 279-281
ISI
000331155300021
Full text (Publisher's DOI)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 17.11.2015
Last edited 23.06.2017
To cite this reference